At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Pre-Mkt 06-25 06:15:19 EDT
2.70
-0.01
-0.37%
盘前2.69
-0.01-0.37%
04:35 EDT
High2.85Low2.53Vol92.40K
Open2.65D1 Closing2.71Amplitude11.83%
Mkt Cap2.87MTradable Cap2.86MTotal Shares1.06M
T/O249.59KT/O Rate8.73%Tradable Shares1.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
TIPRANKS  ·  00:50
Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split
THOMSON REUTERS  ·  06-24 13:39
Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split
Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial
Reuters  ·  06-23 20:40
Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial
Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany
THOMSON REUTERS  ·  06-23 20:40
Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany
Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany
THOMSON REUTERS  ·  06-23 20:40
Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer
Reuters  ·  06-22 20:38
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer
Silexion Therapeutics management to attend BIO International Convention 2026
Reuters  ·  06-17
Silexion Therapeutics management to attend BIO International Convention 2026
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
TIPRANKS  ·  06-13
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
Silexion Therapeutics executes 1-for-10 reverse share split
Reuters  ·  05-29
Silexion Therapeutics executes 1-for-10 reverse share split
Silexion Therapeutics Corp trading halted, news pending
TIPRANKS  ·  05-29
Silexion Therapeutics Corp trading halted, news pending
Silexion Therapeutics announces 1-for-10 reverse share split
Reuters  ·  05-26
Silexion Therapeutics announces 1-for-10 reverse share split
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
THOMSON REUTERS  ·  05-26
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Top Premarket Gainers
MT Newswires Live  ·  05-20
Top Premarket Gainers
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
THOMSON REUTERS  ·  05-18
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026
Reuters  ·  05-16
Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026
Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each
Reuters  ·  05-16
Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
Reuters  ·  05-15
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
GlobeNewswire  ·  05-15
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer
THOMSON REUTERS  ·  05-14
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
GlobeNewswire  ·  05-14
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--